Rodman & Renshaw analyst Brandon Folkes initiated coverage of Eupraxia Pharmaceuticals (EPRX) with a Buy rating and $9 price target
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EPRX: